Phaseline

Companies › Sunhawk Vision Biotech

Sunhawk Vision Biotech: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 2; Ophthalmology; next expected readout Dec 2026.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
SHJ002
Antisense oligonucleotide targeting microRNA
–Phase 2Myopia, ProgressiveDec 2026

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06579287SHJ002Phase 2Myopia, ProgressiveOphthalmologyDec 2026

Targets

No annotated target.

Companies with the same targets

–

Companies built like this

Vantage Biosciences Tourmaline Bio, Inc., a Novartis Company Qingdao WanMing BioCell Pharmaceutics Caravel Oculus Tavo Biotherapeutics

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.